nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.241	0.446	CbGbCtD
Atomoxetine—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.183	0.339	CbGbCtD
Atomoxetine—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.116	0.215	CbGbCtD
Atomoxetine—Micturition urgency—Cyclosporine—focal segmental glomerulosclerosis	0.0134	0.0421	CcSEcCtD
Atomoxetine—Gastrointestinal symptom NOS—Cyclosporine—focal segmental glomerulosclerosis	0.013	0.0406	CcSEcCtD
Atomoxetine—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0112	0.035	CcSEcCtD
Atomoxetine—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.00934	0.0292	CcSEcCtD
Atomoxetine—Dysmenorrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00839	0.0262	CcSEcCtD
Atomoxetine—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00697	0.0218	CcSEcCtD
Atomoxetine—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.00619	0.0194	CcSEcCtD
Atomoxetine—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.00616	0.0193	CcSEcCtD
Atomoxetine—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00597	0.0187	CcSEcCtD
Atomoxetine—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.00592	0.0185	CcSEcCtD
Atomoxetine—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00587	0.0184	CcSEcCtD
Atomoxetine—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00565	0.0177	CcSEcCtD
Atomoxetine—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00549	0.0172	CcSEcCtD
Atomoxetine—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00545	0.0171	CcSEcCtD
Atomoxetine—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.00524	0.0164	CcSEcCtD
Atomoxetine—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.00506	0.0158	CcSEcCtD
Atomoxetine—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.005	0.0157	CcSEcCtD
Atomoxetine—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.00466	0.0146	CcSEcCtD
Atomoxetine—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00459	0.0144	CcSEcCtD
Atomoxetine—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00447	0.014	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00445	0.0139	CcSEcCtD
Atomoxetine—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00442	0.0138	CcSEcCtD
Atomoxetine—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00433	0.0135	CcSEcCtD
Atomoxetine—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.0134	CcSEcCtD
Atomoxetine—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.0134	CcSEcCtD
Atomoxetine—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00425	0.0133	CcSEcCtD
Atomoxetine—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00415	0.013	CcSEcCtD
Atomoxetine—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.004	0.0125	CcSEcCtD
Atomoxetine—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00381	0.0119	CcSEcCtD
Atomoxetine—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00378	0.0118	CcSEcCtD
Atomoxetine—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00375	0.0118	CcSEcCtD
Atomoxetine—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.00355	0.0111	CcSEcCtD
Atomoxetine—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00347	0.0109	CcSEcCtD
Atomoxetine—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00345	0.0108	CcSEcCtD
Atomoxetine—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00344	0.0108	CcSEcCtD
Atomoxetine—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00336	0.0105	CcSEcCtD
Atomoxetine—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00333	0.0104	CcSEcCtD
Atomoxetine—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00329	0.0103	CcSEcCtD
Atomoxetine—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00327	0.0102	CcSEcCtD
Atomoxetine—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00326	0.0102	CcSEcCtD
Atomoxetine—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00324	0.0101	CcSEcCtD
Atomoxetine—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00321	0.01	CcSEcCtD
Atomoxetine—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00314	0.00983	CcSEcCtD
Atomoxetine—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00312	0.00978	CcSEcCtD
Atomoxetine—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00306	0.00959	CcSEcCtD
Atomoxetine—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.003	0.00937	CcSEcCtD
Atomoxetine—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00291	0.00911	CcSEcCtD
Atomoxetine—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00289	0.00904	CcSEcCtD
Atomoxetine—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00284	0.00888	CcSEcCtD
Atomoxetine—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00284	0.00888	CcSEcCtD
Atomoxetine—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00284	0.00888	CcSEcCtD
Atomoxetine—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00283	0.00885	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00282	0.00882	CcSEcCtD
Atomoxetine—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00278	0.00869	CcSEcCtD
Atomoxetine—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.0027	0.00846	CcSEcCtD
Atomoxetine—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00267	0.00835	CcSEcCtD
Atomoxetine—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00264	0.00827	CcSEcCtD
Atomoxetine—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00263	0.00823	CcSEcCtD
Atomoxetine—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00259	0.00812	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00248	0.00776	CcSEcCtD
Atomoxetine—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00246	0.0077	CcSEcCtD
Atomoxetine—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00244	0.00765	CcSEcCtD
Atomoxetine—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00242	0.00757	CcSEcCtD
Atomoxetine—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.00239	0.0075	CcSEcCtD
Atomoxetine—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.0074	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00735	CcSEcCtD
Atomoxetine—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00235	0.00734	CcSEcCtD
Atomoxetine—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00728	CcSEcCtD
Atomoxetine—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.00728	CcSEcCtD
Atomoxetine—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00224	0.00702	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00222	0.00696	CcSEcCtD
Atomoxetine—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00216	0.00677	CcSEcCtD
Atomoxetine—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00215	0.00673	CcSEcCtD
Atomoxetine—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00215	0.00673	CcSEcCtD
Atomoxetine—Fenoprofen—ALB—focal segmental glomerulosclerosis	0.00202	0.221	CrCbGaD
Atomoxetine—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.00611	CcSEcCtD
Atomoxetine—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00603	CcSEcCtD
Atomoxetine—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.00583	CcSEcCtD
Atomoxetine—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.00563	CcSEcCtD
Atomoxetine—Phenprocoumon—ALB—focal segmental glomerulosclerosis	0.00174	0.19	CrCbGaD
Atomoxetine—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00173	0.00541	CcSEcCtD
Atomoxetine—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00537	CcSEcCtD
Atomoxetine—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.00536	CcSEcCtD
Atomoxetine—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.00533	CcSEcCtD
Atomoxetine—Fluoxetine—ALB—focal segmental glomerulosclerosis	0.0017	0.185	CrCbGaD
Atomoxetine—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.00506	CcSEcCtD
Atomoxetine—Warfarin—ALB—focal segmental glomerulosclerosis	0.00155	0.169	CrCbGaD
Atomoxetine—Ketoprofen—ALB—focal segmental glomerulosclerosis	0.00119	0.13	CrCbGaD
Atomoxetine—Nortriptyline—ALB—focal segmental glomerulosclerosis	0.000952	0.104	CrCbGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000554	0.00424	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00055	0.00421	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00055	0.00421	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000539	0.00412	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000536	0.0041	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000531	0.00406	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000529	0.00404	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.000528	0.00404	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000516	0.00395	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000503	0.00385	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.000501	0.00383	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000475	0.00363	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.000472	0.00361	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000471	0.0036	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00047	0.0036	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.00047	0.00359	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000467	0.00357	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—NOS2—focal segmental glomerulosclerosis	0.000462	0.00353	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000461	0.00353	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000461	0.00353	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.000459	0.00351	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000457	0.00349	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000455	0.00348	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000448	0.00343	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000448	0.00342	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000427	0.00326	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000417	0.00319	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00041	0.00314	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—AGT—focal segmental glomerulosclerosis	0.000408	0.00312	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000408	0.00312	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000403	0.00308	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.0004	0.00306	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.0004	0.00306	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.000395	0.00302	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000391	0.00299	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.00039	0.00298	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—SERPINE1—focal segmental glomerulosclerosis	0.000389	0.00298	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.000389	0.00297	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000389	0.00297	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000386	0.00296	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000372	0.00284	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000362	0.00277	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000359	0.00274	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.000354	0.00271	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000354	0.00271	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000351	0.00269	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00035	0.00267	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.000348	0.00266	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000346	0.00265	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000334	0.00256	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000334	0.00256	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000332	0.00254	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000332	0.00254	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000325	0.00249	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000325	0.00248	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.000323	0.00247	CbGpPWpGaD
Atomoxetine—SLC6A4—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000317	0.00243	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000307	0.00234	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000304	0.00233	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.000304	0.00232	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.000301	0.0023	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000298	0.00228	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000297	0.00227	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000296	0.00227	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000296	0.00227	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.000289	0.00221	CbGpPWpGaD
Atomoxetine—SLC6A2—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000273	0.00209	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000272	0.00208	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000267	0.00204	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000266	0.00204	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000266	0.00203	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000265	0.00203	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000264	0.00202	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.00026	0.00199	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000258	0.00198	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.000257	0.00197	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000254	0.00195	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000253	0.00193	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000252	0.00193	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000251	0.00192	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000249	0.00191	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000247	0.00189	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000246	0.00188	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000244	0.00187	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000244	0.00187	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000243	0.00186	CbGpPWpGaD
Atomoxetine—SLC6A3—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	0.000242	0.00185	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000241	0.00185	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000241	0.00184	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	0.000241	0.00184	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000239	0.00183	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000236	0.0018	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000235	0.00179	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000232	0.00177	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.000231	0.00177	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000231	0.00176	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000229	0.00175	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000226	0.00173	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000224	0.00171	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000223	0.00171	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000222	0.0017	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000217	0.00166	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.000214	0.00163	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000209	0.0016	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000204	0.00156	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000203	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000203	0.00155	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000201	0.00154	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000199	0.00152	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000197	0.00151	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000197	0.00151	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.000196	0.0015	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000196	0.0015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000195	0.00149	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000193	0.00148	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000193	0.00148	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000189	0.00145	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000187	0.00143	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000186	0.00142	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000185	0.00141	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000184	0.00141	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00018	0.00138	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000179	0.00137	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000178	0.00136	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000173	0.00133	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000172	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000171	0.00131	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.00017	0.0013	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.00017	0.0013	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000168	0.00129	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000165	0.00126	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	0.000164	0.00125	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000163	0.00124	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000161	0.00123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000161	0.00123	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000157	0.0012	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000156	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000155	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000154	0.00118	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000153	0.00117	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.00015	0.00115	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000149	0.00114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000148	0.00113	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	0.000144	0.0011	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000144	0.0011	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000144	0.0011	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000143	0.0011	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000143	0.00109	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000143	0.00109	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000143	0.00109	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000142	0.00109	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000141	0.00108	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.00014	0.00107	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000139	0.00107	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000139	0.00106	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000138	0.00106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000137	0.00105	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000131	0.001	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000131	0.000999	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.00013	0.000992	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.00013	0.000991	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000128	0.000976	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000127	0.000971	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000125	0.000954	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000123	0.000942	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000122	0.000936	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00012	0.000917	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000119	0.00091	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000119	0.000908	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000116	0.000891	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000116	0.000886	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000111	0.000847	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.00011	0.000838	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000109	0.000832	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000107	0.000815	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000106	0.00081	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000106	0.000808	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000105	0.000803	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000102	0.000776	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000101	0.000769	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	9.98e-05	0.000763	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	9.62e-05	0.000736	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.29e-05	0.000711	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.22e-05	0.000705	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	9.2e-05	0.000703	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	9.17e-05	0.000701	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	9.12e-05	0.000697	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	9.03e-05	0.000691	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LPL—focal segmental glomerulosclerosis	9.02e-05	0.00069	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LPL—focal segmental glomerulosclerosis	8.95e-05	0.000684	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	8.83e-05	0.000675	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LPL—focal segmental glomerulosclerosis	8.76e-05	0.00067	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.54e-05	0.000653	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	8.54e-05	0.000653	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.48e-05	0.000648	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	8.35e-05	0.000639	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	8.3e-05	0.000635	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	8.07e-05	0.000617	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.71e-05	0.00059	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	7.67e-05	0.000586	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.66e-05	0.000586	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGT—focal segmental glomerulosclerosis	7.5e-05	0.000573	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	7.28e-05	0.000557	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.13e-05	0.000545	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—FN1—focal segmental glomerulosclerosis	7.07e-05	0.000541	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	7.01e-05	0.000536	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—FN1—focal segmental glomerulosclerosis	6.93e-05	0.00053	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	6.84e-05	0.000523	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	6.7e-05	0.000512	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LPL—focal segmental glomerulosclerosis	6.64e-05	0.000508	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6.55e-05	0.000501	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	6.41e-05	0.00049	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	6.29e-05	0.000481	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	5.94e-05	0.000455	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.93e-05	0.000454	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.91e-05	0.000452	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	5.9e-05	0.000451	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.89e-05	0.00045	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	5.77e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	5.76e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—focal segmental glomerulosclerosis	5.68e-05	0.000434	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	5.46e-05	0.000418	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.43e-05	0.000416	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—FN1—focal segmental glomerulosclerosis	5.25e-05	0.000401	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	4.93e-05	0.000377	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	4.56e-05	0.000349	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.54e-05	0.000347	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.51e-05	0.000345	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	4.45e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	4.41e-05	0.000338	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	4.38e-05	0.000335	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	4.37e-05	0.000334	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	4.09e-05	0.000313	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	3.86e-05	0.000295	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	3.8e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	3.79e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.74e-05	0.000286	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.72e-05	0.000284	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	3.64e-05	0.000278	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.55e-05	0.000272	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	3.5e-05	0.000268	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	3.35e-05	0.000256	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	2.92e-05	0.000223	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	2.91e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.76e-05	0.000211	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	2.68e-05	0.000205	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	2.67e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2.39e-05	0.000183	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	2.29e-05	0.000175	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	1.75e-05	0.000134	CbGpPWpGaD
